• Brainstorm Health: Alzheimer's Drug Failures, Sage Therapeutics Stock, Azar on Drug Prices

    4 monthes ago - By Fortune

    Good afternoon, readers-This is Sy.
    Of the diseases that regularly afflict millions upon millions of Americans, few have been quite as nefarious as Alzheimer's when it comes to defying drug developers' most ardent efforts. That trend continued Tuesday as Indianapolis-based Eli Lilly and partner AstraZeneca of the U.K. threw in the towel on late-stage clinical trials for an Alzheimer's medicine hopeful. The move, while not entirely unexpected, could telegraph doom for an entire class of experimental treatments called “BACE inhibitors” aimed at treating a disease projected to afflict 15...
    Read more ...